## PHARMACOPOEIAL DISCUSSION GROUP

## Q11

## STERILITY REV. 1

It is understood that sign-off covers the technical content of the draft and each party will adapt it as necessary to conform to the usual presentation of the pharmacopoeia in question; such adaptation includes stipulation of the particular pharmacopoeia's reference materials and general chapters.

European Pharmaco	<b>ppoeia</b> Name	Date
Ceste	LEGITEL	701101200r
Japanese Pharmaco Signature	<b>poeia</b> Name	Date
Digir low fo	Toshiro Nakagaki	Oct 30,2007
United States Pharm	nacopeia Name  I ARRECCE  TBERNATAS	Date 30 Oct, 7027
Local requirements		

## <del>---</del>-

Local requirements

- In the section on « Test for sterility of the product to be examined », USP will add a paragraph on « Number of articles to be tested ».
- USP will add a requirements for testing of for pharmacy bulk packages (this includes description of media for penicillins and cephalosporins; use of alternative micro-organisms to the those indicated in Table 1; description of additional diluting and rinsing fluids for membrane filtration)
- USP will add requirements for medical devices in Table 2